Literature DB >> 34280142

La Crosse Virus Disease in the United States, 2003-2019.

Grace M Vahey1,2, Nicole P Lindsey1, J Erin Staples1, Susan L Hills1.   

Abstract

La Crosse virus (LACV) is an arthropod-borne virus that can cause a nonspecific febrile illness, meningitis, or encephalitis. We reviewed U.S. LACV surveillance data for 2003-2019, including human disease cases and nonhuman infections. Overall, 318 counties in 27 states, principally in the Great Lakes, mid-Atlantic, and southeastern regions, reported LACV activity. A total of 1,281 human LACV disease cases were reported, including 1,183 (92%) neuroinvasive disease cases. The median age of cases was 8 years (range: 1 month-95 years); 1,130 (88%) were aged < 18 years, and 754 (59%) were male. The most common clinical syndromes were encephalitis (N = 960; 75%) and meningitis (N = 219, 17%). The case fatality rate was 1% (N = 15). A median of 74 cases (range: 35-130) was reported per year. The average annual national incidence of neuroinvasive disease cases was 0.02 per 100,000 persons. West Virginia, North Carolina, Tennessee, and Ohio had the highest average annual state incidences (0.16-0.61 per 100,000), accounting for 80% (N = 1,030) of cases. No animal LACV infections were reported. Nine states reported LACV-positive mosquito pools, including three states with no reported human disease cases. La Crosse virus is the most common cause of pediatric neuroinvasive arboviral disease in the United States. However, surveillance data likely underestimate LACV disease incidence. Healthcare providers should consider LACV disease in patients, especially children, with febrile illness, meningitis, or encephalitis in areas where the virus circulates and advise their patients on ways to prevent mosquito bites.

Entities:  

Mesh:

Year:  2021        PMID: 34280142      PMCID: PMC8592351          DOI: 10.4269/ajtmh.21-0294

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   3.707


  18 in total

1.  ISOLATION OF CALIFORNIA ENCEPHALITIS GROUP VIRUS FROM A FATAL HUMAN ILLNESS.

Authors:  W H THOMPSON; B KALFAYAN; R O ANSLOW
Journal:  Am J Epidemiol       Date:  1965-03       Impact factor: 4.897

Review 2.  Arboviral infections in the United States.

Authors:  T F Tsai
Journal:  Infect Dis Clin North Am       Date:  1991-03       Impact factor: 5.982

3.  Evidence that fatal human infections with La Crosse virus may be associated with a narrow range of genotypes.

Authors:  C Huang; W H Thompson; N Karabatsos; L Grady; W P Campbell
Journal:  Virus Res       Date:  1997-05       Impact factor: 3.303

4.  Full genomic characterization of California serogroup viruses, genus Orthobunyavirus, family Peribunyaviridae including phylogenetic relationships.

Authors:  Holly R Hughes; Robert S Lanciotti; Carol D Blair; Amy J Lambert
Journal:  Virology       Date:  2017-10-03       Impact factor: 3.616

5.  Serologic evidence for widespread infection with La Crosse and St. Louis encephalitis viruses in the Indiana human population.

Authors:  P R Grimstad; C L Barrett; R L Humphrey; M J Sinsko
Journal:  Am J Epidemiol       Date:  1984-06       Impact factor: 4.897

6.  Epidemiology of neuroinvasive arboviral disease in the United States, 1999-2007.

Authors:  Carolyn A Reimann; Edward B Hayes; Carolyn DiGuiseppi; Richard Hoffman; Jennifer A Lehman; Nicole P Lindsey; Grant L Campbell; Marc Fischer
Journal:  Am J Trop Med Hyg       Date:  2008-12       Impact factor: 2.345

7.  Age-dependent myeloid dendritic cell responses mediate resistance to la crosse virus-induced neurological disease.

Authors:  Katherine G Taylor; Tyson A Woods; Clayton W Winkler; Aaron B Carmody; Karin E Peterson
Journal:  J Virol       Date:  2014-07-09       Impact factor: 5.103

8.  Comparative sequence analyses of La Crosse virus strain isolated from patient with fatal encephalitis, Tennessee, USA.

Authors:  Amy J Lambert; Rebecca Trout Fryxell; Kimberly Freyman; Armando Ulloa; Jason O Velez; Dave Paulsen; Robert S Lanciotti; Abelardo Moncayo
Journal:  Emerg Infect Dis       Date:  2015-05       Impact factor: 6.883

9.  La Crosse virus: a scoping review of the global evidence.

Authors:  S Harding; J Greig; M Mascarenhas; I Young; L A Waddell
Journal:  Epidemiol Infect       Date:  2018-12-05       Impact factor: 2.451

10.  Notes from the Field: Spatially Associated Coincident and Noncoincident Cases of La Crosse Encephalitis - North Carolina, 2002-2017.

Authors:  Brian D Byrd; Carl J Williams; J Erin Staples; Kristen L Burkhalter; Harry M Savage; Michael S Doyle
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2018-10-05       Impact factor: 17.586

View more
  6 in total

1.  An Overview of La Crosse Virus Disease.

Authors:  Elizabeth Matthews; Lakshmi Chauhan; Amanda L Piquet; Kenneth L Tyler; Daniel M Pastula
Journal:  Neurohospitalist       Date:  2022-02-28

2.  Development of a Community-Driven Mosquito Surveillance Program for Vectors of La Crosse Virus to Educate, Inform, and Empower a Community.

Authors:  Rebecca T Trout Fryxell; Michael Camponovo; Brian Smith; Kurt Butefish; Joshua M Rosenberg; Julie L Andsager; Corey A Day; Micah P Willis
Journal:  Insects       Date:  2022-02-03       Impact factor: 2.769

3.  Metal coordinating inhibitors of Rift Valley fever virus replication.

Authors:  Elizabeth Geerling; Valerie Murphy; Maria C Mai; E Taylor Stone; Andreu Gazquez Casals; Mariah Hassert; Austin T O'Dea; Feng Cao; Maureen J Donlin; Mohamed Elagawany; Bahaa Elgendy; Vasiliki Pardali; Erofili Giannakopoulou; Grigoris Zoidis; Daniel V Schiavone; Alex J Berkowitz; Nana B Agyemang; Ryan P Murelli; John E Tavis; Amelia K Pinto; James D Brien
Journal:  PLoS One       Date:  2022-09-16       Impact factor: 3.752

4.  Targeted Mutations in the Fusion Peptide Region of La Crosse Virus Attenuate Neuroinvasion and Confer Protection against Encephalitis.

Authors:  Bradley S Hollidge; Mary-Virginia Salzano; John M Ibrahim; Jonathan W Fraser; Valentina Wagner; Nicole E Leitner; Susan R Weiss; Friedemann Weber; Francisco González-Scarano; Samantha S Soldan
Journal:  Viruses       Date:  2022-07-02       Impact factor: 5.818

Review 5.  Etiology, Clinical Phenotypes, Epidemiological Correlates, Laboratory Biomarkers and Diagnostic Challenges of Pediatric Viral Meningitis: Descriptive Review.

Authors:  Saleh M Al-Qahtani; Ayed A Shati; Youssef A Alqahtani; Abdelwahid Saeed Ali
Journal:  Front Pediatr       Date:  2022-06-16       Impact factor: 3.569

Review 6.  Human Brain Organoids as Models for Central Nervous System Viral Infection.

Authors:  Josse A Depla; Lance A Mulder; Renata Vieira de Sá; Morgane Wartel; Adithya Sridhar; Melvin M Evers; Katja C Wolthers; Dasja Pajkrt
Journal:  Viruses       Date:  2022-03-18       Impact factor: 5.048

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.